Cervix carcinoma
Not yet recruitingA study of pembrolizumab and lenvatinib for patients with high risk locally advanced cervical cancer after chemoradiotherapy and brachytherapy
A study of pembrolizumab and lenvatinib for patients with high risk locally advanced cervical cancer after chemoradiotherapy and brachytherapy
- Disease:Cervix carcinoma
- Substances:LenvatinibPembrolizumab
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Lenvatinib
- Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)







